Botulinum toxin for the management of spasticity in multiple sclerosis: the Italian botulinum toxin network study

Autor:	Anna Castagna, Calogera Butera, Ubaldo Del Carro, M. Frontoni, S. Lori, Jessica Frau, Giancarlo Coghe, Francesco Bono, Vincenzo Brescia Morra, Antonio Carotenuto, Marcello Moccia, Pamela Latino, Stefania Lanfranchi, Morena Giovannelli, Marcello Romano, Caterina Nascimbene, Laura Rapisarda, P. Barbero, Loredana Maggi, Elisabetta Groppo, Vitalma Liotti, Roberto Eleopra, Cristina Inglese, Marcello Esposito, Maria Concetta Altavista, Emma Frasson, Maria Buccafusca, Salvatore Lo Fermo, Martina Petracca
Přispěvatelé:	Moccia, Marcello, Frau, Jessica, Carotenuto, Antonio, Butera, Calogera, Coghe, Giancarlo, Barbero, Pierangelo, Frontoni, Marco, Groppo, Elisabetta, Giovannelli, Morena, Del Carro, Ubaldo, Inglese, Cristina, Frasson, Emma, Castagna, Anna, Buccafusca, Maria, Latino, Pamela, Nascimbene, Caterina, Romano, Marcello, Liotti, Vitalma, Lanfranchi, Stefania, Rapisarda, Laura, Lori, Silvia, Esposito, Marcello, Maggi, Loredana, Petracca, Martina, Lo Fermo, Salvatore, Altavista, Maria Concetta, Bono, Francesco, Eleopra, Roberto, Brescia Morra, Vincenzo
Rok vydání:	2020
Předmět:	Adult medicine.medical_specialty Multiple Sclerosis Botulinum Modified Ashworth scale Hypophonia Dermatology 03 medical and health sciences 0302 clinical medicine Internal medicine Activities of Daily Living Humans Medicine Multiple sclerosi Symptomatic treatment 030212 general & internal medicine Spasticity Botulinum Toxins Type A Multiple sclerosis Adverse effect Expanded Disability Status Scale business.industry General Medicine Middle Aged Botulinum toxin Clinical trial Psychiatry and Mental health Cross-Sectional Studies Treatment Outcome Italy Neuromuscular Agents Muscle Spasticity Concomitant Female Neurology (clinical) medicine.symptom business 030217 neurology & neurosurgery medicine.drug
Zdroj:	Neurological Sciences. 41:2781-2792
ISSN:	1590-3478 1590-1874
DOI:	10.1007/s10072-020-04392-8
Popis:	Botulinum toxin (BT) is an effective and safe treatment for spasticity, with limited evidence in multiple sclerosis (MS). We aim to describe the use of BT for the management of MS spasticity in the clinical practice, its combination with other anti-spastic treatments in MS and possible MS clinical correlates. This is a multicentre cross-sectional observational study including 386 MS patients, receiving BT for spasticity in 19 Italian centres (age 53.6 ± 10.9 years; female 228 (59.1%); disease duration 18.7 ± 9.2 years; baseline Expanded Disability Status Scale (EDSS) 6.5 (2.0–9.0)). BT was used for improving mobility (n = 170), functioning in activities of daily living (n = 56), pain (n = 56), posturing-hygiene (n = 63) and daily assistance (n = 41). BT formulations were AbobotulinumtoxinA (n = 138), OnabotulinumtoxinA (n = 133) and IncobotulinumtoxinA (n = 115). After conversion to unified dose units, higher BT dose was associated with higher EDSS (Coeff = 0.591; p
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc42de1b2f1d610567dc77dc90f7fd02 https://doi.org/10.1007/s10072-020-04392-8 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.